Rifampicin

Generic Name: Rifampicin

Brand Names: Isonarif, Rifadin, Rifamate, Rifater, Rofact

Drug Type: Small Molecule

Chemical Formula: C_₄₃H_₅₈N_₄O_₁₂

CAS Number: 13292-46-1

Unique Ingredient Identifier: VJT6J7R4TR

Background: A semisynthetic antibiotic produced from Streptomyces mediterranei. It has a broad antibacterial spectrum, including activity against several forms of Mycobacterium. In susceptible organisms it inhibits DNA-dependent RNA polymerase activity by forming a stable complex with the enzyme. It thus suppresses the initiation of RNA synthesis. Rifampin is bactericidal, and acts on both intracellular and extracellular organisms. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p1160)

Indication: Rifampin is indicated for the treatment of tuberculosis and tuberculosis-related mycobacterial infections. In combination with pyrazinamide and isoniazid, it is used in the initial phase of the short-course treatment of pulmonary tuberculosis.

Associated Conditions: Cholestatic pruritus, MRSA Infections, Prosthetic Joint Infections, Asymptomatic Neisseria meningitidis carrier of the nasopharynx, Initial phase Tuberculosis, Late phase Tuberculosis

Associated Therapies: Antibacterial therapy

Clinical Trials

A Study to Evaluate Drug-Drug Interaction of Larotinib With Itraconazole and Rifampin in Healthy Adult Participants

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: Larotinib
Drug: Rifampin
Drug: Itraconazole

First Posted Date: 2021-09-27

Last Posted Date: 2025-05-18

Lead Sponsor: Sunshine Lake Pharma Co., Ltd.

Target Recruit Count: 32

Registration Number: NCT05057949

Locations: 🇨🇳
First Hospital of Jilin University, Changchun, Jilin, China

Four Months Moxifloxacin Containing Daily Regimen Study Among New Pulmonary Tuberculosis Patients

Active, not recruiting

Conditions: Tuberculosis, Pulmonary

Interventions: Drug: Isoniazid
Drug: Rifampicin
Drug: Pyrazinamide
Drug: Ethambutol
Drug: Moxifloxacin

First Posted Date: 2021-09-16

Last Posted Date: 2024-01-05

Lead Sponsor: Tuberculosis Research Centre, India

Target Recruit Count: 550

Registration Number: NCT05047055

Locations: 🇮🇳
National Institute for Research in Tuberculosis, Chennai, Tamilnadu, India

Short-course Rifamycin-based Regimens for Latent Tuberculosis in Patients With End-stage Kidney Disease

Phase 4

Not yet recruiting

Conditions: Latent Tuberculosis
Kidney Failure

Interventions: Drug: Rifampicin plus Isoniazid
Drug: Rifapentine plus Isoniazid
Drug: Rifampicin alone

First Posted Date: 2021-08-25

Last Posted Date: 2024-03-15

Lead Sponsor: Miguel Santín

Target Recruit Count: 225

Registration Number: NCT05021731

A Study to Assess the Effects of Itraconazole, Rifampicin, and Omeprazole on Pharmacokinetics of Adavosertib

Phase 1

Terminated

Conditions: Advanced Solid Tumours

Interventions: Drug: Adavosertib
Drug: Rifampicin
Drug: Itraconazole
Drug: Omeprazole

First Posted Date: 2021-07-13

Last Posted Date: 2022-09-16

Lead Sponsor: AstraZeneca

Target Recruit Count: 5

Registration Number: NCT04959266

Locations: 🇪🇸
Research Site, Malaga, Spain

Testing New Strategies for Patients Hospitalised With HIV-associated Disseminated Tuberculosis

Phase 3

Recruiting

Conditions: Disseminated Tuberculosis
HIV

Interventions: Drug: Prednisone
Drug: Placebo
Drug: Rifampin
Drug: Levofloxacin
Drug: Rifampicin, Pyrazinamide, Ethambutol and Isoniazid

First Posted Date: 2021-07-07

Last Posted Date: 2022-03-31

Lead Sponsor: University of Cape Town

Target Recruit Count: 732

Registration Number: NCT04951986

Locations: 🇿🇦
Mitchells Plain Hospital, Mitchells PLain, Cape Town, Western Cape, South Africa
🇿🇦
Khayelitsha Hospital, c/o Steve Biko and Walter Sisulu Drives, Khayelitsha, Cape Town, Western Cape, South Africa

Drug Interaction Study of ALXN2050 With Fluconazole and Rifampin in Healthy Adult Participants

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: ALXN2050
Drug: Fluconazole
Drug: Rifampin

First Posted Date: 2021-06-22

Last Posted Date: 2022-12-08

Lead Sponsor: Alexion Pharmaceuticals, Inc.

Target Recruit Count: 16

Registration Number: NCT04933682

Locations: 🇺🇸
Clinical Trial Site, Tempe, Arizona, United States

Safety and Tolerability of Metformin in People With Tuberculosis (TB) and Human Immunodeficiency Virus (HIV)

Phase 2

Active, not recruiting

Conditions: Tuberculosis
Pulmonary Tuberculosis
HIV Coinfection

Interventions: Drug: Isoniazid
Drug: Rifampicin
Drug: Ethambutol
Drug: Pyrazinamide
Drug: Metformin hydrochoride

First Posted Date: 2021-06-18

Last Posted Date: 2025-04-23

Lead Sponsor: University of Massachusetts, Worcester

Target Recruit Count: 112

Registration Number: NCT04930744

Locations: 🇿🇦
Tembisa Clinical Research Centre-The Aurum Institute, Johannesburg, Gauteng, South Africa
🇿🇦
Isango Lethemba TB Research Unit, Port Elizabeth, South Africa

Hypertonic Saline for MAC

Phase 4

Recruiting

Conditions: Nontuberculous Mycobacterial Lung Disease
Nontuberculous Mycobacterium Infection

Interventions: Drug: Hypertonic saline
Drug: Azithromycin
Drug: Ethambutol
Drug: Rifampin

First Posted Date: 2021-06-10

Last Posted Date: 2023-12-19

Lead Sponsor: Oregon Health and Science University

Target Recruit Count: 50

Registration Number: NCT04921943

Locations: 🇺🇸
NYU Langone Health, New York, New York, United States
🇨🇦
University Health Network, Toronto, Ontario, Canada
🇺🇸
Oregon Health & Science University, Portland, Oregon, United States